ABIO - ARCA biopharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.81
-0.61 (-8.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.42
Open7.27
Bid0.00 x 4000
Ask6.96 x 900
Day's Range6.79 - 7.76
52 Week Range4.68 - 23.04
Volume123,304
Avg. Volume802,579
Market Cap8.879M
Beta (3Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-8.53
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price
    Simply Wall St.23 days ago

    One Thing To Remember About The ARCA biopharma, Inc. (NASDAQ:ABIO) Share Price

    If you're interested in ARCA biopharma, Inc. (NASDAQ:ABIO), then you might want to consider its beta (a measure of...

  • GlobeNewswirelast month

    ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced it recently filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering Gencaro’s (bucindolol hydrochloride) potential treatment effect in preventing atrial fibrillation (AF) in patients with heart failure (HF). The patent application is based on recent novel findings from the GENETIC-AF Phase 2B study of Gencaro, described in “GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population,” published in JACC: Heart Failure, a journal of the American College of Cardiology.

  • GlobeNewswire2 months ago

    ARCA Biopharma Announces First Quarter 2019 Financial Results and Provides Corporate Update

    WESTMINSTER, Colo., May 08, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.

  • GlobeNewswire2 months ago

    GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population” was published in JACC: Heart Failure, a journal of the American College of Cardiology. The lead author on the paper is Jonathan P. Piccini, MD, MHS, FACC, Director, Duke Center for Atrial Fibrillation, Duke University Medical Center and Duke Clinical Research Institute and the senior author is Stuart J. Connolly, MD, Professor Emeritus, Division of Cardiology at McMaster University in Hamilton, Ontario.

  • GlobeNewswire2 months ago

    ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the initial members of the Steering Committee for PRECISION-AF, the Company’s planned Phase 3 trial evaluating Gencaro™ (bucindolol hydrochloride) as potentially the first genetically-targeted treatment for atrial fibrillation.  The Steering Committee is comprised of experts in the field of cardiology and electrophysiology, particularly in clinical development.  The Company anticipates additional cardiology thought leaders joining the Steering Committee.

  • GlobeNewswire3 months ago

    Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the paper “PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Left Ventricles” was recently published in the Journal of the American College of Cardiology (JACC) (http://www.onlinejacc.org/content/73/10/1173). The lead author on the paper is University of Colorado molecular biologist Carmen Sucharov, PhD and the senior author is Michael R. Bristow MD, PhD, ARCA’s Chief Executive Officer, who is also the Director of the University of Colorado Cardiovascular Institute (CU CVI) Section of Pharmacogenomics.

  • GlobeNewswire4 months ago

    Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine

    WESTMINSTER, Colo., March 06, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.

  • GlobeNewswire4 months ago

    ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

    WESTMINSTER, Colo., Feb. 27, 2019 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.

  • GlobeNewswire4 months ago

    ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug

    FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure.

  • GlobeNewswire5 months ago

    Zosano Appoints Linda Grais M.D., J.D. to Board of Directors

    Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of experience and expertise to Zosano. After graduation from Yale Medical School and residency at UCSF, she was an assistant professor at UCSF in internal medicine, received her J.D. from Stanford Law School where she was an editor of Stanford Law and Policy Review before joining Wilson Sonsini Goodrich & Rosati as an associate representing Life Science companies.

  • ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling
    Simply Wall St.6 months ago

    ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...

  • GlobeNewswire6 months ago

    ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

    ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted an amendment to its Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA).  The amendment addresses FDA feedback and guidance on the target population for ARCA’s planned Phase 3 clinical trial.  The SPA request is part of the Company’s ongoing interaction with the FDA focused on the planned Phase 3 clinical development program of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure (HF). The FDA’s SPA process is designed to facilitate the FDA’s review and approval of drugs by allowing FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product’s efficacy and safety.

  • GlobeNewswire7 months ago

    ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update

    WESTMINSTER, Colo., Nov. 14, 2018 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.

  • GlobeNewswire7 months ago

    GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions

    AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring.

  • GlobeNewswire8 months ago

    ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions

    Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 --  ARCA biopharma,.

  • Westminster biotech company receives second extension on delisting notice from Nasdaq
    American City Business Journals9 months ago

    Westminster biotech company receives second extension on delisting notice from Nasdaq

    ARCA Biopharma, a Westminster biotech company, has been given an additional 180 days to regain compliance with Nasdaq’s $1 per share minimum bid price requirement, according to an SEC form filed Tuesday. “Our Nasdaq listing is obviously very important to the company and our shareholders, so we are very focused on regaining compliance with the Nasdaq minimum closing bid price continued listing requirement,” Derek Cole, the company’s investor relations leader, said in an email. “The additional 180-day compliance period affords ARCA the opportunity to potentially regain compliance.” ARCA Biopharma is the 12th largest biotechnology/biosciences company in Colorado as ranked by number of employees, according to Denver Business Journal research.

  • ACCESSWIRE9 months ago

    Today's Research Reports on Trending Tickers: ARCA biopharma and Nektar Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average ...

  • ACCESSWIRE11 months ago

    Marijuana Stocks: Biotech Stock Report: 3 Companies To Watch In August 2018

    Last month, for instance, GT Biopharma (GTBP) announced a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota. This Major Pharmaceutical Company will be supplying a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

  • ACCESSWIRE11 months ago

    3 Biotech Stocks in Focus on Tuesday

    CORAL GABLES, FL / ACCESSWIRE / July 31, 2018 / The Nasdaq iShares Biotechnology Index (IBB) has taken a turn toward ''greener pastures.'' The ETF rose by more than 1.2% on Tuesday as a number of biotech stocks moved higher in early morning trading. GT Biopharma (GTBP) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms. Earlier this month the company announced the addition of Dr. John N. Bonfiglio to GT Biopharma's Board of Directors.

  • ACCESSWIRE11 months ago

    Today’s Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Biotech stocks Progenics and ARCA biopharma were both soaring on Monday. While ARCA had no news to explain its 40% climb, shares of Progenics soared higher after ...